Susan Monarez Sworn In as New CDC Director | CDC Leadership Update 2025

WASHINGTON—The Centers for Disease Control and Prevention (CDC) has a new director. Susan Monarez, Ph.D., was sworn in today, July 31, 2025, by U.S. Health and Human Services Secretary Robert F. Kennedy, Jr., marking a new chapter for the agency and a renewed focus on what Secretary Kennedy has termed a “Make America Healthy Again” agenda. The appointment comes at a time of ongoing scrutiny of public health institutions and evolving challenges in biosecurity and infectious disease preparedness.

Dr. Monarez is the first Senate-confirmed director of the CDC, bringing with her decades of experience in disaster preparedness, biosecurity, and health innovation. Her career has spanned multiple federal agencies, including roles with the Biomedical Advanced Research and Development Authority at HHS, the Department of Homeland Security, the White House’s Office of Science and Technology Policy, and the National Security Council. Most recently, she served as Acting Director of CDC and Deputy Director for the Advanced Research Projects Agency for Health, where she oversaw advancements in data collection and disease detection technologies.

A Focus on Modernization and Trust

Secretary Kennedy emphasized Dr. Monarez’s “unimpeachable scientific credentials” and expressed confidence in her ability to restore public trust in the CDC. This statement arrives after a period where the agency faced criticism regarding its handling of public health crises and communication strategies. Recent reports indicate that the previous CDC director was ousted after disagreements with Secretary Kennedy regarding the agency’s approach to public health messaging.

Dr. Monarez, in her own statement, highlighted her commitment to strengthening and modernizing the nation’s public health preparedness and response through science and innovation. She acknowledged the privilege of working alongside the dedicated public servants at the CDC and pledged to work collaboratively to achieve the “Make America Healthy Again” vision. This vision, echoing a previous political slogan, suggests a prioritization of domestic health security and a potential shift in the agency’s focus.

The Path to the Directorship: A Background in Biosecurity

Dr. Monarez’s academic background provides a strong foundation for her new role. She earned her PhD in microbiology and immunology from the University of Wisconsin–Madison, focusing her research on technologies for preventing, diagnosing, and treating infectious diseases. Her postdoctoral research fellowship at the Stanford University School of Medicine further honed her expertise in this critical area. This scientific training, combined with her extensive experience in national security and health preparedness, positions her as a leader capable of navigating the complex challenges facing the CDC.

Her work at the Advanced Research Projects Agency for Health (ARPA-H) is particularly noteworthy. ARPA-H is focused on accelerating breakthroughs in health, and Dr. Monarez’s leadership in transforming the agency’s data collection and disease detection capabilities suggests a commitment to leveraging technology to improve public health outcomes. This emphasis on innovation is likely to be a key component of her approach as CDC Director.

What Does “Make America Healthy Again” Mean for the CDC?

The “Make America Healthy Again” agenda, while broadly stated, signals a potential shift in priorities for the CDC. It suggests a focus on preventative measures, strengthening domestic health infrastructure, and addressing emerging health threats. It as well implies a commitment to restoring public confidence in the agency, which has been eroded in recent years by political polarization and misinformation. The CDC’s official announcement frames this agenda as a renewal of the agency’s core mission: preventing disease and defending against health threats.

However, the specific policies and initiatives that will be pursued under this agenda remain to be seen. Given Secretary Kennedy’s past statements and associations, the CDC will adopt a more critical stance towards certain public health interventions, such as vaccine mandates, and prioritize alternative approaches to disease prevention. Reports have surfaced indicating disagreements between the previous CDC director and Secretary Kennedy regarding public health messaging, suggesting a potential for significant changes in the agency’s communication strategy.

Navigating the Complex Landscape of Public Health

The CDC faces a multitude of challenges in the coming years, including the ongoing threat of emerging infectious diseases, the rise of antimicrobial resistance, and the increasing prevalence of chronic diseases. Addressing these challenges will require a multifaceted approach that combines scientific innovation, robust surveillance systems, and effective public health communication. Dr. Monarez’s experience in biosecurity and disaster preparedness will be invaluable in navigating these complex issues.

the CDC must work to rebuild public trust and address the growing skepticism towards public health institutions. This will require transparency, honesty, and a commitment to evidence-based decision-making. Dr. Monarez’s emphasis on science and innovation suggests a willingness to embrace these principles.

Looking Ahead: CDC Priorities and Surveillance

The CDC’s immediate priorities are likely to include strengthening its surveillance systems to detect and respond to emerging health threats, modernizing its data infrastructure to improve disease tracking and analysis, and enhancing its communication strategies to effectively convey public health information. The agency will also need to continue its efforts to address health disparities and promote health equity.

Ongoing surveillance programs, such as those monitoring influenza, COVID-19, and other infectious diseases, will be crucial for identifying outbreaks and tracking the spread of disease. The CDC will also need to invest in research to develop new diagnostic tools, treatments, and vaccines. The agency’s success in these endeavors will depend on its ability to attract and retain talented scientists and public health professionals.